Abstract
Eosinophils are clearly participants in allergic diseases and have effector roles in promoting the pathogenesis of these diseases. Indeed, the number of eosinophils and its secretory products are elevated in allergic inflamed tissues and have been shown to positively correlate with the severity of the disease.1-3Thus, new therapies for allergic disorders could be aided by the development of anti-eosinophilic tools. The most potent agents currently used for controlling severe eosinophilic reactions, including asthma, are the glucocorticoids4. However, the adverse effects of long term treatment with glucocorticoids have stimulated efforts to identify effective anti-inflammatory substitutes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G.J. Gleich, C.R. Adolphson, and K.M. Leiferman. The biology of eosinophilic leukocyte.Annu. Rev. Med. 44:85 (1993).
P.F. Weller. Human eosinophils.J. Allergy Clin. Immunol.100:283 (1997).
M.E. Rothenberg. Eosinophilia.N. Engl. J. Med.28:1592 (1998).
P.J. Barnes. Drug therapy: Inhaled glucocorticoids for asthma.N. Engl. J. Med.332: 868 (1995).
C.N. Serhan. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?Prostaglandins53:107 (1997).
C.N. Serhan, T. Takano, and J.F. Maddox. Aspirin-triggered 15-epi-lipoxin A4 and stable analogs on lipoxin A4 are potent inhibitors of acute inflammation. Receptors and pathways.In Lipoxygenases and Their Metabolites. Nigam and Pace-Asciak, editors. Plenum press, New York. p. 133 (1999).
T.H. Lee, A.E. Crea, V. Gant, B.W. Spur, B.E. Marron, K.C. Nicolaou, E. Reardon, M. Brezinski, and C.N. Serhan. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases.Am. Rev. Respir. Dis.141:1453 (1990).
C. Edenius, M. Kumlin, T. Bjork, A. Anggard, and J.A. Lindgren. Lipoxin formation in human nasal polyps and bronchial tissue.FEBS Lett.272:25 (1990).
B.D. Levy, J.M. Drazen, and C.N. Serhan. Agonist-induced lipoxin A4 generation in vitro and in aspirin-sensitive asthmatics: detection by a novel lipoxin A4-ELISA.Adv. Exp. Med. Biol.400B:611 (1997).
C.N. Serhan, U. Hirsch, J. Palmblad, and B. Samuelsson. Formation of lipoxin A by granulocytes from eosinophilic donors.FEBS Lett.217.242 (1987).
O. Soyombo, B.W. Spur, and T.H. Lee. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine.Allergy49:230 (1994).
C.J. Sanderson. Interleukin-5, eosinophils and disease.Blood79:3101 (1992).
A.D. Luster, and M.E. Rothenberg.Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation.J Leukoc. Biol.62:620 (1997).
P.M. Silva, M.A. Martins, M.C. Lima, A.C. Alves, B.L. Diaz, and R.S.B. Cordeiro. Pharmacological modulation of the late eosinophilia induced by antigen in actively sensitized rats.Int. Arch. Allergy Immunol.98:355 (1992).
C.P. Pasquale, M.C. Lima, C. Bandeira-Melo, R.S. Cordeiro, P.M. Silva, and M.A. Martins. Systemic and local dexamethasone treatments prevent allergic eosinophilia in rats via distinct mechanisms.Eur. J. Pharmacol.26:67 (1999).
C.P. Pasquale, P.M.R. e Silva, M.C. Lima, B.L.Diaz, J.P. Rihoux, B.B. Vargaftig, R.S. Cordeiro and M.A. Martins. Suppression by cetirizine of pleurisy triggered by antigen in actively sensitized rats. Eur J Pharmacol. 223:9 (1992).
C. Bandeira-Melo, P.T. Bozza,B.L. Diaz,R.S.B. Cordeiro,P.J. Jose, M.A. Martins and C.N. Serhan. Lipoxin (LX) A4and aspirin-triggered 15-epi-LXA4block allergen-induced eosinophil trafficking.J. Immunol.164: 2267 (2000).
C. Bandeira-Melo, M.F. Serra, B.L. Diaz, R.S.B. Cordeiro, P.M.R. Silva, H.L. Lenzi, Y.S. Bakhle, C.N. Serhan and M.A. Martins. COX-2-derived prostaglandin E2 and Lipoxin A, accelerate resolution of edema in Angistrongilus costaricensis-infected rats: relationship with concurrent eosinophilia.J. Immunol.164: 1029 (2000).
T. Takano, S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petasis, and C.N. Serhan. Aspirin-triggered 15-epilipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.J. Exp. Med.185:1693 (1997).
M.J. Sanz, P.D. Ponath, C.R. Mackay, W. Newman, M. Miyasaka, T. Tamatani, B.F. Flanagan, R.R. Lobb, T.J. Williams, S. Nourshargh, and P.J. Jose. Human eotaxin induces alpha 4 and beta 2 integrin-dependent eosinophil accumulation in rat skin in vivo: delayed generation of eotaxin in response to IL-4. J. Immunol. 160:3569 (1998).
M. Hachicha, M. Pouliot, N.A. Petasis, and C.N. Serhan. Lipoxin (LX)A4 and aspirin-triggered 15-epiLXA4 inhibit tumor necrosis factor lalpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis.J. Exp. Med.189:1923 (1999).
K. Gronert, A. Gewirtz, J.L. Madara, and C.N. Serhan. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J. Exp. Med. 187:1285 (1998).
A.T. Gewirtz, B. McCormick, A.S. Neish, N.A. Petasis, K. Gronert, C.N. Serhan, and J. L. Madara. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. J. Clin. Invest. 101:1860 (1998).
P.E. Christie, B.W. Spur, and T.H. Lee. The effects of lipoxin A4 on airway responses in asthmatic subjects.Am. Rev. Respir. Dis.145:1281 (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bandeira-Melo, C. et al. (2002). Inhibition of Allergen-Induced Eosinophil Migration by Lipoxin (LX)A4and Aspirin-Triggered 15-Epi-LXA4 . In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E., Serhan, C. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5. Advances in Experimental Medicine and Biology, vol 507. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0193-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0193-0_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4960-0
Online ISBN: 978-1-4615-0193-0
eBook Packages: Springer Book Archive